Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine – Journal of Clinical Oncology ̵
Reporting from:
– 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004
– New England Journal of Medicine
– Journal of Clinical Oncology
– European Journal of Cancer
– Science
– PNAS
In this edition:
Articles in the New England Journal of Medicine on metastatic colorectal cancer are reviewed by George Canellos, who discusses treatment with bevacizumab combined with an irinotecan regimen. Robert Mayer comments on the prospects for developing combinations of targeted therapies for colorectal cancer.
John Hainsworth presented his results at the ASCO conference on treatment of patients with advanced renal cancer with two targeted therapies combined: elotinib and bevacizumab.
The superiority of exemestane over tamoxifen for metastatic breast cancer
was claimed by Robert Paridaens during the New Orleans Meeting in the light of his phase III study findings.
Michele Saunders discusses her New England Journal editorial about two studies in which cisplatin has been added to radiotherapy for treating patients with head and neck cancer.
…
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon